Literature DB >> 8699214

Age and severe adverse drug reactions caused by nifedipine and verapamil. Gruppo Italiano di Farmacovigilanza nell' Anziano (GIFA).

M Pahor1, A Manto, C Pedone, L Carosella, J M Guralnik, P Carbonin.   

Abstract

The association of age with risk for severe adverse drug reactions (SADRs) was studied in 2371 and 862 hospitalized patients taking nifedipine and verapamil, respectively. Nifedipine caused hypotension (n = 22), tachycardia (n = 3), and acute renal failure (n = 1) (total SADR rate, 1.1%, 26/2371). Verapamil caused hypotension (n = 3), bradycardia (n = 9), and atrioventricular blocks (n = 2) (total SADR rate, 1.6%, 14/862). The mean age of patients with and without SADRs was for nifedipine 77.1 +/- 1.7 and 71.8 +/- 0.8 years, respectively (p < 0.05), and for verapamil 73.4 +/- 2.9 and 73.1 +/- 0.4 years, respectively. Sex, length of stay, comorbidity, polypharmacy, intake of slow-release preparations, daily dosage, and new intake of calcium antagonists were examined as potential confounders of the age-SADR association. After adjusting for potential confounders, age was significantly and independently associated with SADRs caused by nifedipine, but not with SADRs caused by verapamil (OR = 1.69, 95% CI = 1.05-2.72 and OR = 1.06, 95% CI = 0.63-1.68 for 10-year increase, respectively). Although nifedipine and verapamil did not have significantly different rates of SADRs, an age-related gradient was found only for nifedipine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8699214     DOI: 10.1016/0895-4356(96)00056-x

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  6 in total

1.  Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions.

Authors:  L Naldi; A Conforti; M Venegoni; M G Troncon; A Caputi; E Ghiotto; A Cocci; U Moretti; G Velo; R Leone
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

2.  Use of calcium antagonists and worsening renal function in patients receiving angiotensin-converting-enzyme inhibitors.

Authors:  Giuseppe Zuccalà; Graziano Onder; Claudio Pedone; Matteo Cesari; Emanuele Marzetti; Alberto Cocchi; Pierugo Carbonin; Roberto Bernabei
Journal:  Eur J Clin Pharmacol       Date:  2003-01-31       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

4.  A whole of population retrospective observational study on the rates of polypharmacy in New Zealand 2014 to 2018 Polypharmacy in New Zealand: What is the current status?

Authors:  James Nind; Alesha Smith; Manjula Devananda; Benoit Auvray
Journal:  Health Sci Rep       Date:  2021-03-10

Review 5.  Pharmacogenetics in Primary Headache Disorders.

Authors:  Irina I Belyaeva; Anna G Subbotina; Ivan I Eremenko; Vadim V Tarasov; Vladimir N Chubarev; Helgi B Schiöth; Jessica Mwinyi
Journal:  Front Pharmacol       Date:  2022-02-10       Impact factor: 5.810

6.  Verapamil and vasospastic angina: underuse in the elderly population.

Authors:  Xavier Humbert; Vincent Roule; Paul Milliez; Joachim Alexandre
Journal:  J Geriatr Cardiol       Date:  2017-07       Impact factor: 3.327

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.